A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 1
Not yet recruiting
56
2026-07
Industry sponsor intelligence
Eli LillyClinical Pipeline.
Lead-sponsor view of Eli Lilly's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 85
- Recruiting
- 20
- Active
- 15
- Completed
- 49
- Results posted
- 16
- Avg enrollment
- 715
Pipeline overview
Programs by phase and activity.
Velocity
Eli Lilly trials by start year
Study start year · indexed snapshot
Development
Trials by phase
84phase labels
Early Phase 10
Phase 135
Phase 214
Phase 329
Phase 46
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Dulaglutide → | 14 | 5 | 2 | 5 | 2 | 3 |
| Tirzepatide → | 13 | 0 | 3 | 8 | 2 | 11 |
| Teriparatide → | 2 | 0 | 0 | 0 | 2 | 0 |
| Retatrutide → | 33 | 15 | 3 | 14 | 0 | 10 |
| Eloralintide → | 20 | 10 | 5 | 5 | 0 | 14 |
| Glucagon → | 9 | 1 | 3 | 5 | 0 | 6 |
| Mazdutide → | 7 | 4 | 3 | 0 | 0 | 1 |
| Semaglutide → | 3 | 1 | 2 | 0 | 0 | 2 |
| Goserelin → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Eli Lilly · Obesity · Weight Gain
Phase 3
Recruiting
300
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly · Type 2 Diabetes
Phase 3
Recruiting
55
2026-07
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly · Type 2 Diabetes
Phase 2
Recruiting
240
2026-07
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly · Ulcerative Colitis · Obesity or Overweight
Phase 3
Recruiting
350
2026-07
Showing 10 of 35 studies
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Eli Lilly · Healthy
Phase 1
Completed
30
2026-07
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Eli Lilly · Alcohol Use Disorder
Phase 2
Completed
308
2026-07
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly · Type 2 Diabetes Mellitus
Phase 3
Completed
13,299
2026-07
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Eli Lilly · Obesity · Obese
Phase 2
Completed
507
2026-07
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Completed
263
2026-06
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Eli Lilly · Type 2 Diabetes Mellitus
Phase 1
Completed
80
2026-06
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly · Psoriasis · Obesity
Phase 3
Completed
281
2026-06
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 3
Completed
2,335
2026-06
Showing 10 of 49 studies
Search sponsor records
All Eli Lilly studies.
This page groups studies where Eli Lilly is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
85 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07738614A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightJul 31, 2026NCT05882045A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseJul 30, 2026NCT05929079A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightJul 30, 2026NCT07035093A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainJul 23, 2026NCT06143956A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightJul 20, 2026NCT06297603Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Jul 20, 2026NCT06383390The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Jul 20, 2026NCT06439277A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)Jul 20, 2026NCT06662383A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityJul 20, 2026NCT06739122A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)Jul 20, 2026